Zerion Pharma A/S - CVR: 40169229

2023, DKK

15.07.2024

Bruttoresultat

-5.253'

Primær drift

-11.947'

Årets resultat

-11.102'

Aktiver

8.472'

Kortfristede aktiver

5.846'

Egenkapital

-13.731'

Afkastningsgrad

-141 %

Soliditetsgrad

-162 %

Likviditetsgrad

207 %

Resultat

15.07.2024

Årsrapport	2023 15.07.2024	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Nettoomsætning	3.559.956	3.273.327	1.932.775
Bruttoresultat	-5.253.393	-10.912.651	-6.714.675	0	-1.068.242
Resultat af primær drift	-11.947.148	-20.891.826	-13.179.938	-3.740.154	-1.346.954
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	2.974	3.832	5.276	0	0
Finansieringsomkostninger	0	0	0	-271.269	0
Andre finansielle omkostninger	-1.561.471	-1.241.102	-571.127	0	0
Resultat før skat	-13.505.645	-22.129.096	-13.745.789	-4.011.423	0
Resultat	-11.101.891	-18.857.318	-11.134.049	-3.477.649	-1.050.624
Forslag til udbytte	0	0	0	0	0

Aktiver

15.07.2024

Årsrapport	2023 15.07.2024	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	3.546.331	5.373.907	4.938.666	2.248.514	455.240
Likvider	2.299.974	4.103.621	6.644.491	3.948.613	579.287
Kortfristede aktiver	5.846.305	9.477.528	11.583.157	6.197.127	1.034.527
Immaterielle aktiver og goodwill	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0
Materielle aktiver	2.625.902	2.945.727	2.114.467	802.626	0
Langfristede aktiver	2.625.902	2.945.727	2.114.467	802.626	0
Aktiver	8.472.207	12.423.255	13.697.624	6.999.753	1.034.527

Aktiver

15.07.2024

Passiver

15.07.2024

Årsrapport	2023 15.07.2024	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Forslag til udbytte	0	0	0	0	0
Egenkapital	-13.730.512	-9.958.078	-866.830	-1.029.105	31.476
Hensatte forpligtelser	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld		0	0	6.374.078	0
Leverandører af varer og tjenesteydelser	1.536.084	1.987.244	2.366.480	760.479	391.246
Kortfristede forpligtelser	2.818.642	4.432.315	3.984.981	1.654.780	1.003.051
Gældsforpligtelser	22.202.719	22.381.333	14.564.454	8.028.858	1.003.051
Forpligtelser	22.202.719	22.381.333	14.564.454	8.028.858	1.003.051
Passiver	8.472.207	12.423.255	13.697.624	6.999.753	1.034.527

Passiver

15.07.2024

Nøgletal

15.07.2024

Årsrapport	2023 15.07.2024	2022 29.06.2023	2021 07.06.2022	2020 11.05.2021	2019 05.05.2020
Afkastningsgrad	-141,0 %	-168,2 %	-96,2 %	-53,4 %	-130,2 %
Dækningsgrad	-147,6 %	-333,4 %	-347,4 %	Na.	Na.
Resultatgrad	-311,9 %	-576,1 %	-576,1 %	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	80,9 %	189,4 %	1.284,5 %	337,9 %	-3.337,9 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	-1.378,8 %	Na.
Soliditestgrad	-162,1 %	-80,2 %	-6,3 %	-14,7 %	3,0 %
Likviditetsgrad	207,4 %	213,8 %	290,7 %	374,5 %	103,1 %

Resultat

15.07.2024

Gæld

15.07.2024

Årsrapport

15.07.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 15.07.2024)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C. The accounting policies applied to these financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:13 Assets charged and collateralThe Company does not have pledges or collaterals.

Oplysning om eventualaktiver:11 Contingent assetsThe Company has total tax assets of a tax base of DKK 4,817k which are not recognised in the financial statements due to the uncertainty of utilising the tax assets. The Company has a tax loss carryforward of DKK 4,985k.

Beretning

15.07.2024

Dato for ledelsens godkendelse af årsrapporten:2024-06-28

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Zerion Pharma A/S for the financial year 01. 01. 2023 - 31. 12. 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesZerion Pharma A/S (“Zerion” or “the Company”) is a drug development company, based in Copenhagen. The Company was founded in January 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion has developed a formulation technology, Dispersome®, that enables poorly soluble drugs to become effective pharmaceutical products. The Company applies the technology to 1) improve existing drug products, thereby building its own pipeline of product candidates and 2) partner with major pharmaceutical and biotech companies to solve problems with solubility and bioavailability in their new pharmaceutical candidates (NCEs). Zerion’s R&D activities comprise firstly in-house lab work with the aim to develop better formulations of new and existing drugs. The Company’s research labs are located at the incubator centre, Symbion, where the Company employs about 10 scientists and technicians. Secondly, Zerion conducts external pre-clinical and eventually clinical studies with selected drug candidates which incorporate the Dispersome® technology.